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Rabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization
Can Mimic the Antigen-Binding Modes of Antibodies Derived from
HIV-1-Infected Humans
Ruimin Pan,a Jared M. Sampson,a Yuxin Chen,b Michael Vaine,b Shixia Wang,b Shan Lu,b Xiang-Peng Konga
Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, USAa; Department of Medicine, University of
Massachusetts Medical School, Worcester, Massachusetts, USAb
The rabbit is a commonly used animal model in studying antibody responses in HIV/AIDS vaccine development. However, no
rabbit monoclonal antibodies (MAbs) have been developed previously to study the epitope-specific antibody responses against
HIV-1 envelope (Env) glycoproteins, and little is known about how the rabbit immune system canmimic the human immune
system in eliciting such antibodies. Here we present structural analyses of two rabbit MAbs, R56 and R20, against the third vari-
able region (V3) of HIV-1 gp120. R56 recognizes the well-studied immunogenic region in the V3 crown, while R20 targets a less-
studied region at the C terminus of V3. By comparison of the Fab/epitope complex structures of these two antibodies raised by
immunization with that of the corresponding human antibodies derived from patients chronically infected with HIV-1, we
found that rabbit antibodies can recognize immunogenic regions of gp120 andmimic the binding modes of human antibodies.
This result can provide new insight into the use of the rabbit as an animal model in AIDS vaccine development.
Animal models are indispensable in the development of HIV/AIDS vaccines. A comparison of the structure and function of
monoclonal antibodies (MAbs) derived from animal models with
MAbs derived from human patients will tell us (i) how animal
immune systems mimic the human immune system in humoral
responses and (ii) how animal antibodies derived by immuniza-
tion differ from antibodies derived from chronically infected pa-
tients. This information will help us to optimize vaccine designs.
The rabbit is a unique animal model with many advantages. First,
rabbits are known to be able to produce high-affinity antibodies
against molecules that may not be immunogenic to mice, another
commonly used animalmodel (1). Second, studies have suggested
that the rabbit immune system is more similar to the immune
systems of primates and humans than to that ofmice (2–5). Third,
rabbit immunoglobulin loci have been well characterized and are
relatively simple (1, 6, 7). In addition, rabbits can produce anti-
bodies with a long complementarity-determining region (CDR) 3
in the heavy chain or CDR H3 (5), a property often found in
potent human anti-HIV gp120 MAbs (8). Finally, rabbits, unlike
mice, can provide a sufficient amount of serum for evaluation by
neutralization and other assays.
Rabbit antibodies have certain unique features (1). For the
light chains, there are four common allotypes, b4, b5, b6, and b9,
all belonging to the kappa-1 gene family. For the heavy chain,
about 80 to 90% use a VH1 germ line gene with diversity derived
from gene conversion and somatic hypermutations (9). The three
major heavy-chain allotypes, a1, a2, and a3, differ in frame regions
1 and 3. Even though the rabbit heavy chain has limited combina-
tory possibilities, rabbits are still able to produce a diverse set of
kappa genes for the light chain, resulting in antibodies with a
broad range of diversity (10). Interestingly, there is a unique in-
terdomain disulfide bond linking the variable and constant do-
mains of the kappa light chain, usually between residues 80 (Kabat
numbering; 11) and 170 (residue 171 in the previous literature)
and less frequently between residues 108 and 170 (12, 13). This
disulfide bondwas suggested to help increase the stability of rabbit
antibodies for a long shelf life (1).
We have carried out an extensive HIV/AIDS vaccine study us-
ing rabbits as the animal model and have generated a panel of
rabbit MAbs that provide a unique opportunity to study their
structures by protein crystallography (62). Here we present struc-
tural analyses of two rabbitMAbs against the third variable region
(V3) of HIV-1 gp120. V3 plays a key role in virus entry into the
host cell, participating in the binding of the CCR5 or CXCR4
coreceptor (14–17). V3 is about 35 amino acids in length, and the
structure of full-lengthV3 in the context of the gp120 core showed
that it can be divided into three regions, the base in the gp120 core
(residues 296 to 300 and 326 to 331), the flexible stem (residues
301 to 303 and 319 to 325), and the crown at the distal apex (304 to
318) (18, 19). The V3 crown can be further divided into three
smaller regions, the arch of the beta hairpin of the V3 crown (con-
sisting of residues 312 to 315), the band (residues 304 to 305 and
317 to 318), and the circlet between the arch and the band, which
is more genetically diverse than the other two regions (19). The
amino acid sequence of the arch is often GPGR in clade B strains
and GPGQ in non-clade B strains.
There are many anti-V3 MAbs derived from human patients,
as well as from animalmodels other than the rabbit (20–24).Most
of the known anti-V3 MAbs are against the V3 crown; only a few
of them target the C-terminal region, including a mouse MAb
raised by immunization with a synthetic peptide (25). Several re-
cently described highly potent human MAbs, including PGT128,
are also against the C-terminal region of V3, as well as its associ-
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ated glycans (26). Many of the anti-V3MAbs are characterized by
structuralmethods, including protein crystallography and the nu-
clear magnetic resonance (NMR) method (19, 27–40). These
structural studies of MAbs against the V3 crown showed that they
have, in general, two antigen-binding modes. (i) In the “ladle”
mode, the antibodies have a longCDRH3 (the handle of the ladle)
interacting with the main chain of the N-terminal beta strand of
the V3 crown and a pocket at the base of the CDRH3 (the bowl of
the ladle) interacting with the apex beta turn of the V3 crown. (ii)
In the “cradle” mode, the antigen lies along a long binding groove
resembling a cradle (19, 38, 39). The former is represented by
human MAb 447-52D, and the latter is represented by several
human MAbs, including MAb 2557, encoded by the IGHV5-51
genes (19, 38).
We present here several Fab/epitope complex structures of
rabbit anti-V3MAbs R56 and R20 that had been raised by immu-
nization with gp120 of clade B strain JR-FL by using the DNA
prime-protein boost regimen (41). The epitopes of R56 and R20
have beenmapped to the V3 crown and the V3 C-terminal region,
respectively. R56 has been shown to neutralize SF162 and
MW965.26, and it also neutralizes ss1196, QH0692, and bal.26
with modest activities, but R20 does not neutralize the strains
tested (62). By analyzing the antigen-antibody interactions of
theseMAbs and comparing themwith those of human andmouse
anti-V3 antibodies, we showed that immunization of rabbits with
HIV-1 gp120 can elicit anti-V3 crown antibodies with a binding
mode similar to that of human IGHV5-51 antibodies and that this
immunization can also produce rabbit antibodies that target an
epitope in the C-terminal region that overlaps the epitope of hu-
man MAb PGT128.
MATERIALS AND METHODS
Fab production and purification. Rabbit MAbs R56 and R20 were de-
rived from aNew ZealandWhite rabbit immunized with gp120 of clade B
strain JR-FL by using a DNA prime-protein boost regimen, and hybrid-
oma production was carried out by a contracted service (Epitomics, Bur-
lingame, CA) (62). Epitope mapping by using overlapping peptides of
gp120 showed that the epitope of R56 is at the crown of gp120 V3, while
that of R20 is in the C-terminal region of V3. The details of the production
and antigenicity characterization of these and related MAbs will be pub-
lished separately (62). The Fab fragments of R56 and R20 were prepared
by papain digestion as described previously (38). Briefly, the IgG mole-
cules were mixed with papain at a 20:1 molar ratio and 100 mM Tris (pH
6.8) with 1 mM cysteine hydrochloride and 4 mM EDTA. The mixture
was incubated for 1 h at 37°C, and the reaction was stopped by adding 10
mM iodoacetamide. The Fab molecules were separated from the Fc frag-
ments and the undigested IgG by protein A affinity chromatography, fur-
ther purified by size exclusion chromatography, and concentrated to 10
mg/ml for crystallization.
Crystallization, data collection, structure determination and refine-
ment. For R56, we have crystallized the Fab with two V3 peptides, one
derived from HIV-1 strain JR-FL (V3JR-FL [NNTRKSIHIG PGRAFY
TTGE IIG], residues 301 to 324 in the HXB2 numbering scheme) and
another from the consensus A sequence (V3conA [NNTRKSIRIG PGQAF
YATGD IIG], residues 301 to 324). These peptides were synthesized by
commercial sources. For R20, we have crystallized the Fab with a peptide
derived from the consensus B sequence (V3conB [TTGEIIGDIRQAHCN],
residues 319 to 332), and the peptide was obtained from the NIH AIDS
Research and Reference Reagent Program (peptide 8842 from the set of
HIV-1 consensus subtype B Env [15-mer] peptides). All of the peptides
were dissolved inwater to a concentration of 10mg/ml andmixedwith the
Fab molecules in excess at a 10:1 molar ratio before crystallization by the
hanging-drop method. The optimized crystallization condition (well so-
lution) for complexes of Fab R56/V3s is 26% polyethylene glycol (PEG)
6000, 1 M LiCl, and 0.1 M Tris (pH 8.0), while that for the Fab R20/V3
complex is 1.5 M ammonium sulfate, 1.7% PEG 400, 85 mM sodium
cacodylate (pH 6.5), and 15% (vol/vol) glycerol. We have also crystallized
Fab R20 alone with 1.4 M ammonium sulfate, 1.7% PEG 400, 85 mM
HEPES (pH7.5), and 15%glycerol. For data collection, crystals of FabR56
complexes were soaked briefly in the crystallization solution with an ad-
ditional 20% glycerol before being flash frozen in liquid nitrogen, while
those of Fab R20 were frozen directly. All X-ray diffraction data sets were
collected at beam line X6A, National Synchrotron Light Source (NSLS),
Brookhaven National Laboratory, and processed with the HKL2000 soft-
ware package (42). The structures were determined bymolecular replace-
ment withMOLREP in the CCP4 software package (43). The structures of
Fab R56 complexes were solved first with a starting model built on a
homologous Fab (Protein Data Bank [PDB] accession no. 2X7L), and the
Fab structure of R56 was then used as the starting model for Fab R20
structures. Cycles of manual adjustments and refinements of the struc-
tures were carried out with COOT and PHENIX (44, 45). The final struc-
tural analysis and figure rendering were carried out with the PyMOL and
ICM software packages (46, 47) and the web tools PISA (www.ebi.ac.uk
/msd-srv/prot_int/pistart.html) for hydrogen bonds and Abnum (www
.bioinf.org.uk/abs/abnum/) for application of the Kabat residue-number-
ing scheme.
FIG 1 Structure of Fab R56 in complex with V3JR-FL. (A) Ribbon representa-
tion of a front view of the Fab R56/V3JR-FL complex with the light and heavy
chains and the V3 epitope colored cyan, green, and magenta, respectively (a
coloring scheme kept throughout this report, except where indicated other-
wise). Disulfide bonds are shown by side chain sticks. (B) Side view of the
complex. (C) Top view of the complex looking at the antigen-binding site of
Fab R56. TheCDRs are labeled and colored differently from the rest of the Fab.
(D) Surface representation of Fab R56 colored according to its electrostatic
surface potentials, with the negatively charged region in red and the positively
charged region in blue. V3 is shown as a ribbon. The inset is the sequence of the
peptide used for crystallization, and the magenta residues are those visualized
in the crystal structure.
Pan et al.
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Protein structure accession numbers. The atomic coordinates of the
structures of the Fab R56/V3JR-FL, Fab R56/V3conA, Fab R20/V3Cterm, and
Fab R20/PEG complexes have been deposited in the Research Collabora-
tory for Structural Bioinformatics PDB and assigned accession numbers
4JO1, 4JO2, 4JO3, and 4JO4, respectively.
RESULTS
Determination of the structures of Fabs R56 and R20. We first
determined the crystal structures of Fab R56 in complex with its
epitope, which was mapped to the crown region of V3 (Fig. 1 and
Table 1). We crystallized Fab R56 in complex with two different
V3 peptides, NNTRKSIHIG PGRAFYTTGE IIG (V3JR-FL), de-
rived from the clade B strain JR-FL, and NNTRKSIRIG PGQAFY
ATGD IIG (V3conA), derived from the consensus A sequence of
gp120. These two peptides were selected because JR-FL gp120 was
the one used to immunize the rabbit and the consensus A se-
quence has a GPGQ motif in the crown arch, representing non-
clade B HIV-1 strains. We determined the Fab R56/V3JR-FL and
Fab R56/V3conA complex structures by molecular replacement
and refined them to 2.0 Å and 2.5 Å resolutions, respectively (Fig.
1; Table 1). The crystals of both complexes belong to monoclinic
space groupP21with essentially the sameunit cell parameters. The
two Fab/V3 complexes in the asymmetry unit are highly similar
(for example, the root mean square deviation [RMSD] for super-
imposition of all of the C- atoms is 0.16 Å in the R56/V3JR-FL
complex). We therefore, for simplicity, refer to only one of the
complexes. We assigned the chain identities (IDs) L, H, and P,
respectively, to the light and heavy chains and the epitope of the
first Fab/V3 complex in the asymmetric unit. We numbered the
residues of the light and heavy chains by following the Kabat and
Wuconvention, applied to the coordinateswith theAbnum server
(48), and the residues of V3 in the HXB2 numbering scheme (49).
A residue is referred to by its number preceded by its chain ID, for
example, ArgP315 refers to arginine residue 315 of the V3 epitope.
Although 23-mer peptides were used for crystallization, only 10
residues, from ThrP303 to GlyP314 of the V3 crown region, with the
sequence TRKSIHIGPG for V3JR-FL or TRKSIRIGPG for V3conA,
were observed in the electron densities and have thus been built
into the final structures (Fig. 1). Since the R56/V3conA structure
has a slightly twinned data set with a lower resolution (Table 1)
and is essentially the same as that of Fab R56/V3JR-FL, we have not
included it here but the atomic coordinates have been deposited in
the PDB.
We then determined the crystal structure of Fab R20 in com-
plex with its epitope, which was mapped to the C-terminal region
of V3 (Fig. 2 and Table 1).We crystallized the Fab fragment of R20
in complexwith a 15-merV3 peptide of the consensus B sequence,
TTGEIIGDIR QAHCN (V3conB). The complex structure was de-
termined by molecular replacement and refined to 2.6 Å resolu-
tion (Fig. 2 and Table 1). The crystals belong to the orthorhombic
space group P212121 with two Fab/V3 complexes in the asymmet-
ric unit. Again we refer to only one of the complexes in this report,
as the structures of the two complexes are highly similar (RMSDof
superimposition of all C-  0.55 Å). We have numbered the
residues of the Fab R20/V3 complex in the same way as those of
TABLE 1 Crystallization data collection and refinement statistics
Parameter
Result(s)a for Fab:
R56/V3JRFL R56/V3conA R20/V3conB R20/PEG
Data collection
Space group P21 P21 P212121 P212121
Cell dimensions
a, b, c (Å) 70.51, 74.34, 84.43 69.84, 74.35, 84.96 70.223, 118.977, 134.946 70.649, 119.690, 135.337
, ,  (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (Å) 2.03 (2.07–2.03) 2.50 (2.54–2.50) 2.60 (2.64–2.60) 2.27 (2.31–2.27)
Rmerge 8.5 (45.0) 16.1 (58.7) 15.9 (66.4) 10.7 (59.3)
I/I ratio 18.8 (2.4) 8.9 (2.6) 11.1 (2.7) 22.5 (3.8)
% Completeness 99.5 (94.2) 93.7 (89.9) 97.6 (95.4) 99.9 (99.5)
Redundancy 4.2 (3.8) 3.9 (4.0) 5.7 (5.6) 8.2 (8.1)
Refinement
Resolution (Å) 36.23–2.03 26.46–2.50 38.05–2.60 38.27–2.27
No. of reflections 56,014 30,171 34,658 53,548
Rwork/Rfree ratio 18.13/22.32 18.95/26.54 18.45/23.45 18.43/22.64
No. of atoms
Protein 6,447 6,336 6,670 6,566
Solvent 805 479 369 730
B factors
Protein 27.9 24.11 41.1 29.1
Solvent 34.9 22.08 31.3 34.3
RMSD
Bond lengths (Å) 0.008 0.008 0.009 0.008
Bond angles (°) 1.168 1.147 1.188 1.088
a Values in parentheses are for the outer resolution shell.
Comparison of Rabbit and Human Anti-HIV-1 Antibodies
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the R56/V3 complex. Although a 15-mer peptide was used for
crystallization, only nine residues, GluP322 to AlaP329 of the V3
C-terminal region, with the sequence EIIGDIRQA, were ob-
served. We have also crystallized Fab R20 alone without any pep-
tides and refined the structure to 2.27 Å resolution (Table 1).
Interestingly, an elongated PEGmolecule from the crystallization
conditionwas found at the same position of the boundV3 epitope
in the R20/V3conB complex structure. We have not included the
Fab R20/PEG structure here, but the atomic coordinates have
been deposited in the PDB.
Overall structural features of rabbit antibodies.Our crystal-
lographic analyses of Fabs R56 and R20 have revealed and ex-
plained several salient features of the overall structures of rabbit
antibodies.
(i) Structural basis for rabbit heavy-chain allotype recogni-
tion. The three major allotypes, a1, a2, and a3, are detectable with
antiallotype antisera raised by immunizing rabbits of one type
with IgG of another type. The allotype markers are located at the
first and third frame regions of the heavy chain. Sequence align-
ment showed that bothR56 andR20 belong to the a3 allotype (Fig.
3A). Thus, the frame regions of Fabs R56 and R20 are highly sim-
ilar and superimposed well (Fig. 4). Homology structural model
building of the VH domains for the a1 and a2 allotypes showed
that the surface charges of the first and third frame regions of all
three allotypes are substantially different from each other (Fig. 3B
to D). Thus, any antibodies that recognize this region of one allo-
type will not be able to bind the same region of another allotype.
(ii) An interdomain disulfide bond (Fig. 4D and E).Both R56
and R20 have an interdomain disulfide bond in the elbow region
of the light chain, linking residue 80 of the variable region (VL)
with residue 170 of the first constant region (CL1) (Fig. 4D). This
limits the variation of the elbow angles in the antibodies, with 142°
for R56 and 154° for R20. Some rabbit antibodies were predicted
to have an alternative disulfide bondbetween residues 108 and 170
(20). Our structures showed that this is possible as the distance
between the C- atoms of these two residues is5.6 Å (Fig. 4D),
a suitable distance for disulfide bond formation. However, this
alternative disulfide bond may have less restriction for the elbow
angles in the antibodies.
(iii) Other noncanonical disulfide bonds among the CDR
loops. There are two additional noncanonical disulfide bonds in
R56 andR20. One is unique to R56 in CDRL3 betweenCysL94 and
CysL95D (Fig. 4E). This disulfide bond is involved in a van der
Waals contact with the hydrophobic residues of the V3 epitope
(Fig. 5). A search of the GenBank database found at least three
sequences of rabbit light chains with a similar disulfide bond se-
quence (CSSADC) in CDR L3. We have also observed a similar
disulfide bond in CDR H3 of a human antibody (CPGGSC; un-
published), a rare observation in human antibodies. Another non-
canonical disulfide bond, present in both R56 and R20, is between
CysH35A and CysH50, linking CDRs H1 and H2 (Fig. 4E). While
this report was being prepared, an uncomplexed structure of the
Fab fragment of a rabbit antibody specific for amyloid prefibrillar
oligomer appeared in another publication (50) and the light-chain
interdomain disulfide bond was discussed there.
Antigen-binding mode of R56. The structures of R56/V3
complexes showed that R56 binds the V3 crown by using the cra-
dle-binding mode (Fig. 1 and 5), similar to that of the human
anti-V3 IGHV5-51 MAbs (19, 39). Its antigen-binding site is
shaped like a cradle between the light and heavy chains 14 Å
deep and 10 Å wide with CDR L3 at one end of the cradle and
CDR H3 at the other end (Fig. 1C and 5A). Similar to that of the
human anti-V3 crown MAbs, the antigen-binding site of R56 has
a negative charge contributed in part by three CDR residues from
the light chain (AspL50, AspL93, and AspL95C) and three CDR resi-
dues from the heavy chain (AspH34, GluH52, and AspH101), all lo-
cated at the periphery of the cradle. The bottom of the cradle is
very hydrophobic and is formed by residues AlaL34, LeuL49, LeuL89,
CysL94, CysL95D, and AlaL96 from the light chain and residues
CysH50 and PheH96 from the heavy chain (Fig. 5). The aforemen-
tioned two noncanonical disulfide bonds (CysH35A-CysH50 and
CysL94-CysL95D) in the CDRs both contribute to this hydrophobic
base. Interestingly, the epitope of R56 superimposed well on that
of MAb 447-52D (RMSD  0.75 Å with the superimposed C-
atoms of eight residues [P305 to P314]), even though the latter
belongs to the ladle V3-binding mode.
Our Fab R56/V3 complex structures showed that the epitope
recognized byR56 consists of 10 amino acids (P303 to P314) in the
N-terminal half of the V3 crown (Fig. 1 and 5). The N terminus of
the epitope harbors two highly conserved positively charged band
residues (ArgP304 and LysP305), and the C terminus ends with the
highly conserved GlyP312 ProP313 GlyP314 sequence of the crown
arch. The epitope lies along the cradle with its N terminus sitting
FIG 2 Structure of Fab R20 in complex with V3conB. (A) Ribbon representa-
tion of a front view the Fab R20/V3conB complex. (B) Side view of the complex.
(C) Top view of the complex looking at the antigen-binding site of Fab R20
with the CDRs labeled and colored differently from the rest of the Fab. (D)
Surface representation of Fab R20 colored according to its electrostatic surface
potentials. The inset is the sequence of the peptide used for crystallization, and
the magenta residues are those visualized in the crystal structure.
Pan et al.
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on top of the disulfide bond (CysL94-CysL95D) of CDR L3 and its C
terminus extending toward CDRH3. The antigen-antibody inter-
actions buried a total surface area of 750 Å2 with 356 Å2 from the
antibody and 394 Å2 from the epitope. There are three key com-
ponents of the antigen-antibody interactions (Fig. 5). The first is a
salt bridge between band residue ArgP304 of the epitope and
AspH34 of CDR H1. Negatively charged GluH52 sits on the top of
ArgP304, leaving the salt bridge largely buried. The second is the
hydrophobic interactions between highly conserved circlet resi-
dues IleP307 and IleP309 of the epitope and the hydrophobic base of
the antigen-binding site, burying these two isoleucines in the cen-
ter of the cradle. The third is ProP313 at the GPG beta turn stacking
with the side chain of TyrL49 in CDR L2. Interestingly, the side
chain of circlet residue HisP308 (ArgP308 in V3conA) in the center of
the epitope points away from the antibody toward the solvent;
thus, it does not contribute to the antigen-antibody interaction.
Therefore, R56 does not distinguish the sequence difference be-
tween JR-FL and consensus A (data not shown). There are at
least two facts explaining the broad reactivity of R56 (62). (i) The
interacting residues in the three key components are highly con-
served among HIV-1 strains, and (ii) the side chain of variable
residue HisP308/ArgP308 is not involved in the antigen-antibody
interaction. It is also clear from the structures that R56 will not be
able to bind gp120 of 92UG021, a clade D strain with the sequence
VSYRTPIGVG (from 303 to 314) in the epitope region of R56
(62). In particular, the region of the antigen-binding site that fits
SerP306 in JR-FL will not be able to accommodate the long side
chain of an Arg in the case of 92UG021. Similarly, R56 will not
bind gp120 of the MN strain, which also has an Arg at position
P306. In addition, R56 does not neutralize commonly used strain
IIIB because it has a QR insertion in the V3 crown just before the
GPG turn, and Gln has a large side chain, which does not fit the
space that is occupied by GlyP312 in the JR-FL/conA complex
structures.
Antigen-binding mode of R20. R20 has a long CDR H3 of 21
amino acids, unlike R56, which has a short CDR H3 of only 4
amino acids (Kabat definition). CDR H3 of R20 forms a beta
hairpin standing tall at the center of its antigen-binding site (Fig.
2). This conformation is similar to that of several human and
rhesusMAbs, such as quaternary neutralizing epitopeMAbs 2909
and 2.5B (51). Residues at the top of the other CDR loops form a
pedestal-like structure. This pedestal is roughly 30Å long and 10Å
wide and is contributed about equally by the light chain at one end
and the heavy chain at the other end. The antigen-binding site of
R20 runs across the light chain and heavy chain; this is again dif-
ferent from that of R56, whose antigen-binding site groove is the
chasm between the light and heavy chains.
Our Fab R20/V3conB complex structure showed that the
epitope recognized by R20 consists of nine amino acids (P322 to
P329, including a numbering insertion for IleP322A in the HXB2
scheme) of theC-terminal region ofV3 (Fig. 2 and 6). This epitope
is shaped like a fishhook lying on the top of the pedestal of the
antigen-binding site. A short two-residue beta strand (GlyP324 and
AspP326) in the N-terminal half of the epitope—the shank of the
fishhook—forms a parallel beta sheet with the C-terminal strand
of the CDRH3 hairpin. This beta-sheet-type interaction is similar
to the ladle antigen-binding mode described for anti-V3 MAbs
447-52D and 537 (38). Following the beta strand, a short 310 G
FIG 3 Surface analyses of the three allotypes of rabbit antibodies. (A) Sequence alignment of the heavy-chain Fv regions of R56 and R20 with those of rabbit
major heavy-chain germ line allotypes a1, a2, and a3. The intensity of the green color indicates the conservation of the sequence regions. Cysteine residues of the
conserved canonical Fv disulfide bond are shaded yellow, and the cysteine residues of the noncanonical disulfide bonds in allotype a3 are indicated by
yellow-filled circles above the alignment. Computational modeling of the heavy-chain Fv regions of germ line allotypes a1 and a2 (B and C) on the basis of the
structure of R56 (a3) (D). The electrostatic surface potentials of all three allotypes are shownwith the allotypemarker regions facing forward. (E) The heavy-chain
Fv of R56 is shown as a ribbon for a reference. The ribbon is colored from the N terminus (purple) to the C terminus (orange).
Comparison of Rabbit and Human Anti-HIV-1 Antibodies
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helical turn (IleP326, ArgP327,and GlnP328)—the bend of the fish-
hook—extends toward the light-chain side of the pedestal. In-
terestingly, it was previously predicted by sequence analysis
that the C-terminal region of V3 has a tendency to form a short
alpha helix (52), and it was reported that the V3 C-terminal
strand could form a helical conformation in an NMR study of a
cyclic V3 peptide (53). However, this region of the full-length
V3 structures in the context of the gp120 core does not contain
any helical conformation (18, 54). Taken together, these data
suggest that this region of V3 is very flexible and it can have
many different conformations.
The antigen-antibody interactions buried a total of 804 Å2 of
surface area with 344 Å2 from the antibody and 460 Å2 from the
epitope. TyrH100G on theC-terminal strand of theCDRH3hairpin
bisects the antigen-antibody interactions (Fig. 6). The antigen-
antibody interactions at the N terminus of the epitope have two
components centered at residues GluP322 and IleP322A, respectively
(Fig. 6). First, negatively charged residue GluP322 interacts with
ArgH54, forming a hydrogen bond with its amide group. Second,
the side chain of hydrophobic residue IleP322A is buried by the side
chains of TyrH52 and IleH56 on one side and by the backbones of
TyrH100G and SerH100H on the other side. The antigen-antibody
interactions at the C terminus of the epitope have three compo-
nents centered at residues AspP325, IleP326, and ArgP327, respec-
tively (Fig. 6). First, AspP325 near the middle of the epitope is
buried in the center of the antigen-binding site and its side chain
can form hydrogen bonds with the side chains of SerL92 and
TyrH100K and the backbone amide of IleL94. Second, the side chain
of hydrophobic IleP326 is buried by the side chain of TyrL92 on the
one side and by the side chains of ValH100 and TyrH100G on the
other side. Third, positively charged ArgP327 (shaped like the bait
on the fishhook) forms a salt bridge with AspL1, the first residue of
the light chain. Three negatively charged residues in the light
chain, AspL1, GluL27, and AspL95A, encircle the side chain of
ArgP327, holding it at the center of this highly negatively charged
environment.
Comparison with the binding modes of mouse and human
anti-V3 MAbs. By comparing the antigen-binding mode of R56
with those of all of the available complex structures of anti-V3
MAbs, we found that the antigen-binding mode of mouse MAb
50.1 (IgG2a) is the most similar one (Fig. 7A). Mouse MAb 50.1,
although also produced by immunization, was induced by using
the disulfide-linked 40-mer cyclic peptide RP70 (INCTRPNYNK
RKRIHIGPGR AFYTTKNIIG TIRQAHCNIS), which contains
the V3 sequence of strain MN of HIV-1 gp120 (20). The complex
structure of MAb 50.1 was resolved to 2.8 Å resolution by cocrys-
tallizing its Fab with another cyclic peptide, MP1 (CKRIHIGPGR
AFYTTC) (27). The N-terminal nine amino acids of the peptide
were observed in the structure, including the first Cys, a non-
HIV-1 amino acid. Only the N-terminal half of the crown hairpin
was observed in the 50.1 complex structure, as in the case of R56,
although a cyclic peptide was used. Notably, the sequences of the
epitopes of MAbs 50.1 and R56 are derived from the same region
of the V3 crown, and the structures of the epitopes have the same
3D shape (Fig. 7B), with an RMSD of 0.57 Å for superimposition
of the C- atoms of P305 to P314. The Fv domains of MAbs 50.1
and R56 also superimpose well, with an RMSD of 0.73 Å for the
C- atoms. The details of the antigen-antibody interactions of the
two MAbs have several similarities. First, both MAbs have an an-
tigen-binding site shaped like a cradle running along the interface
between the light and heavy chains (Fig. 7A). Second, both anti-
gen-binding sites have a hydrophobic base, burying highly con-
served IleP307 and IleP309. Third, MAb 50.1 also harbors TyrL49 in
its CDR L2 and stacks ProP313 in the same manner as that of
MAb R56.
Some human anti-V3 MAbs also have a binding mode similar
to that of R56. The best example is the family of anti-V3 MAbs
encoded by IGHV5-51 germ line genes, including MAbs 1006,
2219, 2557, 2558, and 4025 (22, 39). The binding mode of this
humanMAb family has a couple of similarities to that of R56 and
FIG 4 Structural comparison of rabbit MAbs R56 and R20. (A) Superimpo-
sition of the Fv regions of R56 (cyan and green) and R20 (gray for both light
and heavy chains). The RMSD for superimposition of the C- atoms is 0.6 Å
(195 atom pairs). (B) Superimposition of the light chains of the Fv regions of
R56 and R20. The RMSD of the superimposed C- atoms is 0.4 Å (88 atom
pairs). (C) Superimposition of the heavy chains of the Fv regions of R56 and
R20. TheRMSD for superimposition of theC- atoms is 0.4 Å (97 atompairs).
(D) Interdomain disulfide bond of the kappa light chain. R56 and R20 both
have the disulfide bond between residues L80 and L170. The distance between
L108 (Gly in the case of R56 and R20) and L170 is also indicated, as an alter-
native disulfide bond can form between some of the rabbit kappa light chains.
(E) Schematics of the disulfide bonds of R56 and R20. Note that in addition to
the interdomain disulfide bond shown in panel D, R56 and R20 have several
noncanonical disulfide bonds, including the inter-CDR disulfide bond be-
tween residues H35A and H50 in both MAbs and the intra-CDR L3 disulfide
bond between L94 and L95D in MAb R56. Dashed lines indicate a potential
disulfide bond between residues H128 and H213 of R20 because residue H213
was not visualized in the crystal structure, likely because of the flexibility of the
terminal regions.
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50.1. First, all of theseMAbs have a cradle-shaped antigen-binding
site with a hydrophobic base that binds conserved N-terminal
circlet residues IleP307 and IleP309 of the V3 crown. Structure su-
perimposition showed that the epitope of R56 and the N termini
of the epitopes of IGHV5-51 anti-V3 MAbs are very similar; e.g.,
the structure superimposition of V3JR-FL bound to R56 with the N
terminus of V3NY5 bound to human MAb 2557 has an RMSD of
1.7Å (Fig. 7C). Second, ProP313 in theGPG turn of theV3 epitopes
bound by the IGHV5-51 anti-V3 MAbs is stacked by a van der
Waals interaction against the side chain of a tyrosine (TyrL32)
from the CDR L1 region (19), although in the case of R56, ProP313
is packed against a tyrosine from theCDRL2 region, TyrL49. How-
ever, the binding mode of the human IGHV5-51 anti-V3 MAbs
also has a couple of differences from that of MAbs R56 and 50.1.
First, the whole beta hairpin of the V3 crown is visible in all of the
Fab/epitope complex structures of human IGHV5-51 MAbs,
while only the N-terminal half of the V3 crown hairpin could be
observed in the complex structures of R56 and 50.1. The C-termi-
nal half of the V3 crown hairpin was also observed in the complex
structure of mouse MAb 0.5 determined by an NMR study (55).
InterestinglyMAb0.5was raised by immunization of IIIB gp120,
which is different from mouse MAb 50.1, which was raised by a
cyclic peptide. Thus, gp120 itself may be able to elicit in mice
antibody responses with a more complex epitope. Second, the
orientation of the antigen-binding cradle of the IGHV5-51 MAbs
is perpendicular to that of R56 and 50.1. In the human case, the
epitope bridges the two chains, with the arch of the V3 crown
binding the light chain and the band binding the heavy chain (Fig.
7D and E).
The recently identified highly potent humanMAb PGT128 has
an epitope region that overlaps that of R20. PGT128 binds the
mannose glycans harbored by two glycosylation sites (AsnP301 and
AsnP332) at the base of V3 (40). It also engages amino acids in the
C-terminal region of V3 through its CDRH3 by a beta-sheet-type
interaction. The key interacting V3 amino acids are residues P323
to P327 (IGDIR), which are at the core of the R20 epitope. Nev-
ertheless, the conformation of the PGT128 epitope is rather dif-
ferent from that of the R20 epitope, reflecting the flexibility of the
V3 stem. Interestingly, PGT128 also has a noncanonical disulfide
bond betweenCDRsH1 andH2 that plays a critical role in antigen
binding; removing it will make PGT128 lose its gp120-binding
activity (40).
FIG 5 Antigen-antibody interactions in the Fab R56/V3JR-FL complex. (A) Stereo view of the antigen-binding site. Side chains are displayed for key residues
involved in the hydrogen bonding and van derWaals interactions (with contact areas greater than 10 Å2). For simplicity, the chain IDs are not shown in residue
labels because the chains are already indicated by the coloring scheme. (B) Schematic illustration of antigen-antibody interactions. Hydrogen-binding interac-
tions are indicated by dashed lines between the residues, while van der Waals contacts are indicated by eyelashes. Residues in solid ovals contribute to the
interactions by their main chain atoms, and those in dashed ovals contribute by their side chain atoms.
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DISCUSSION
We present Fab/epitope complex structures of two rabbit MAbs,
R56 and R20, raised by immunization with gp120 of HIV-1 clade
B strain JR-FL with a DNA prime-protein boost regimen. These
structures show that they recognize two V3 regions known to be
immunogenic in humans—the crown located at the apex and the
C-terminal region, including residues from both the V3 stem and
base regions (56, 57). R56 has a cradle antigen-bindingmode sim-
ilar to that of a panel of human anti-V3 antibodies encoded by
IGHV5-51 germ line genes. Antibodies with this binding mode
focus their antigen binding on the highly conserved residues at the
N terminus of the V3 crown, consistent with their broad antigen-
binding activities. Our analyses further support the notion that
the V3 crown has a shape that naturally fits the cradle-binding
mode of antibodies. Antibodies with this binding mode are pref-
erentially encoded in humans by the IGHV5-51 germ line genes,
making it possible to design a vaccine that elicits antibodies en-
coded by a specific germ line to target the highly immunogenic V3
crown.
R20 recognizes an epitope consisting of amino acids P322 to
P329, just preceding the disulfide bond at the V3 base (CysP296-
CysP331). This region is spatially close to the two highly conserved
glycosylation sites (AsnP301 and AsnP332) near the V3 base. The
glycans harbored by these two sites have been shown to be part of
the epitope of hyperpotent human MAb PGT128 and related
MAbs (26). There is also a mouse MAb, IIIB-V3-01, generated by
immunization with a linear V3 peptide (FVTIGKIGNM RQA
HC), with an epitope mapped to the V3 C-terminal sequence
IGKIGNMRQ (25). Unlike PGT128, which has broadly potent
neutralization activity, R20 does not neutralize the strains tested
(62). There are several potential reasons for this difference. First,
the epitope of R20 has a shape very different from that of the V3
region bound by PGT128. Superimposition of the two epitopes
showed that only the last five residues of the R20 epitope adopt a
FIG 6 Antigen-antibody interactions in the Fab R20/V3conB complex. (A) Stereo view of the antigen-binding site. Side chains are displayed for key residues. (B)
Schematic illustration of the antigen-antibody interactions. The short beta strand in the epitope is indicated by a pink arrow, and the short 310 G turn is indicated
by a pink shed.
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conformation similar to that of the PGT128 epitope. Second, the
epitope of PGT128 consists mainly of glycans harbored by N301
and N332 while our mutagenesis study suggested that R20 does
not need glycan for binding (data not shown). Third, R20 ap-
proaches the V3 base from an angle tilted about 20° from that of
PGT128; this lower approach angle likely hinders its ability to bind
gp120 in the trimeric conformation. Nevertheless, the overlap-
ping of the epitopes of MAbs R20, IIIB-V3-01, and PGT128 sug-
gests that this V3 C-terminal region is immunogenic and a target
of first immune responses (57). Structurally designed immuno-
gens that target this V3 C-terminal region may induce precursor
antibodies with a potential to mature into antibodies that can
recognize the glycans at the V3 base in a way that mimics that of
PGT128.
Our study of R56 and R20 revealed several features that are
unique to rabbit antibodies. (i) We observed that the commonly
occurring kappa chain interdomain disulfide bond between
CysL80 and CysL170 is located in the elbow region (see also refer-
ence 50). It limits the flexibility of the elbow, hence the flexibility
of the Fab region of the antibody. Limiting of flexibility not only
can contribute to the stability of rabbit antibodies (1) butmay also
help to increase their binding affinity, as it reduces the entropy of
the antibodies. (ii) In addition to this interdomain disulfide bond,
we have also observed several noncanonical disulfide bonds
among the CDR loops. It is known that noncanonical disulfide
bonds are found with relatively low frequency in human and pri-
mate antibodies but often in those of chickens, camels, etc. (58–
61). Formation of the noncanonical disulfide bonds among the
CDR loops increases the variability of CDRs (10). Our data
showed that these disulfide bonds can be involved in antigen bind-
ing, contributing to the affinity of antibodies. (iii) On the basis of
our structures, we computationally modeled the other two major
heavy-chain allotypes (a1 and a2) of rabbit antibodies and showed
that their allotype marker regions have very different electrostatic
surface potentials, providing a structural understanding of the
differences among these three allotypes (Fig. 3). (iv) It is known
that rabbit antibodies have CDRH3s with lengths ranging from 3
to 22 amino acids (Kabat scheme) (5). Here, R56 has a CDRH3 of
only 4 amino acids while R20 has one of 21 amino acids. Interest-
ingly both MAbs were generated from the same rabbit by immu-
nization. These data suggested that the rabbit has the potential to
produce highly diverse antibodies with a wide range of CDR H3
lengths.
There are clearly differences between the epitopes recognized
by the rabbit MAbs raised by immunization and those recognized
by human MAbs derived from chronically infected patients. This
can best be understood in the case of R56, as we have for compar-
ison many structures of human anti-V3 MAbs with the same an-
tigen-binding mode. Previous structural data showed that the C-
terminal residues of the V3 crown are visible in the complex
structures of the human anti-V3 MAbs because these residues
engage the antibody by specific interactions sufficient to stabilize
the C terminus of the V3 crown (19, 35, 39). For rabbit antibody
R56, on the contrary, only theN-terminal half of theV3 crown can
be observed in the complex structures. Since the V3 crown tends
to have a beta hairpin structure, its C-terminal half must be spa-
tially close to the N-terminal half. However, R56 did not develop
contacts with the C terminus of the V3 crown or the contacts were
not sufficiently strong to stabilize theC-terminal half to be observ-
able in the crystal structure (butmay be observable in NMR struc-
tures 55). This is also the case for mouse MAb 50.1, which was
raised by immunization as well. Thus, we hypothesize that, be-
cause of the limited time intervals and insufficient antigen stimu-
lation in immunization, the immunization-derived antibodies do
not have the necessary affinity maturation to develop strong con-
tacts with the C terminus of the V3 crown.
Our structural analyses of R56 and R20 show from several as-
pects the suitability of using the rabbit as an animal model for
AIDS vaccine development. First, the rabbit immune system is
able to respond to gp120 immunogens and recognizes immuno-
genic regions similar to those recognized by the human immune
system, such as the crown and C-terminal regions of V3. Second,
antibodies elicited by gp120 immunogens in rabbits can mimic
the binding modes of human antibodies. This is most clear in the
case of antibodies that target the V3 crown. Third, rabbits can
produce antibodies with CDR H3s with a wide length range, in-
cluding antibodies with very long CDR H3s, a hallmark increas-
ingly found in potent humanMAbs. Fourth, the long CDRH3s of
rabbit antibodies can engage antigen through a beta-sheet-type
interaction, a feature often observed in human MAbs with long
CDRH3s. Taken together, our data show that the rabbit is a useful
animal model in which to test immunogens and immunization
regimens in AIDS vaccine development.
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